We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kronos Bio Inc | NASDAQ:KRON | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.96% | 1.03 | 1.02 | 1.03 | 1.04 | 1.02 | 1.04 | 48,893 | 20:22:42 |
Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 5, at 9:10 a.m. ET.
A live audio webcast of the event will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be available for 30 days following the event.
About Kronos Bio, Inc.Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in clinical trials as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn.
Media Contact:Sarah ConnorsVice President of Corporate Affairs, Kronos Bio857-290-7305sconnors@kronosbio.com
Investor Contact:Margaux BennettVice President, Business Development and Investor Relations, Kronos Bio650-781-5026mbennett@kronosbio.com
1 Year Kronos Bio Chart |
1 Month Kronos Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions